Date: 2015-03-05
Type of information: Licensing agreement
Compound: 3D-Screen technology
Company: Inflectis Bioscience (France) Valneva (France)
Therapeutic area: Technology - Services
Type agreement: licensing
Action mechanism: The 3D-Screen technology enables identification of the small molecules that alter the three-dimensional structure of a target protein. These structural alterations modulate the molecular interactions of the target protein and may lead to either inhibition or activation of its biological activity. This assay opens the way to the identification of original and novel structural modulators, such as allosteric and cellular cofactor modulators.
The 3D-Screen Technology is a cell-based, target-oriented, HTS-compatible assay that was developed and validated by Valneva on a series of nuclear receptors and viral targets. These are notoriously difficult to target pharmacologically, proving the technology\'s ability to identify original small molecules that would be hard to identify using classical screening techniques.
The 3D-Screen technology is applicable to a broad range of target proteins: including, for example, intracellular proteins such as
kinases and phosphatases, and nuclear receptors.
Disease:
Details: * On March 5, 2015, InFlectis BioScience, a pharmaceutical drug discovery company focused on degenerative diseases caused by protein misfolding, has announced that it has exclusively licensed the protein-protein interaction drug discovery platform 3D-Screen from its developer, Valneva. The agreement grants InFlectis BioScience an exclusive worldwide license to the intellectual property rights in the 3D-Screen technology for use in all therapeutic applications, with the exception of hepatitis C. Valneva retains the rights to use this technology in the field of infectious diseases. The agreement also gives InFlectis BioScience rights to conduct research and development for third parties, using the technology.
InFlectis BioScience will use the technology in its quest to discover first-in-class molecules that improve cells’ ability to deal with the accumulation of misfolded proteins. The company’s objective is to strengthen its pipeline which currently comprises a promising preclinical-stage candidate drug, IFB- 088, and a second chemical series for the treatment of protein misfolding diseases.
Incorporated in 2013, InFlectis BioScience develops new molecules for the treatment of diseases whose etiology lies in the accumulation of misfolded proteins. Its pre-clinical drug candidate, IFB-088, targets the so-called “orphan” neurodegenerative
diseases. In addition, the company is developing new chemical series for the treatment of protein misfolding disease.
Financial terms: Financial terms haven\'t been disclosed.
Latest news:
